Citrullination enhances the activity, stability and autoantigenicity of serine proteases in Rheumatoid Arthritis
This study demonstrates that peptidyl arginine deiminase (PAD)-mediated citrullination of serine proteases in rheumatoid arthritis enhances their enzymatic activity and stability, confers autoantigenicity, and drives joint tissue damage, suggesting PAD inhibition as a potential therapeutic strategy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Rheumatoid arthritis is a condition where the body's immune system mistakenly turns against its own joints, causing pain, swelling, and eventual damage. For decades, scientists have known that a specific chemical change in the body's proteins plays a central role in this disease. This change, called citrullination, happens when an enzyme swaps one building block of a protein for another, effectively altering the protein's shape and electrical charge. In people with rheumatoid arthritis, the immune system creates antibodies that hunt down these altered proteins, treating them as foreign invaders. While researchers have long understood that these altered proteins trigger the immune attack, they have not fully understood what the chemical change actually does to the proteins themselves. Does it simply mark them for destruction, or does it change how they work?
A team of researchers from the University of Manitoba and the University of Colorado has now uncovered a surprising answer. They discovered that citrullination does not just mark proteins; it supercharges them. By studying a group of enzymes known as serine proteases, which act like molecular scissors to cut other proteins, the scientists found that when these enzymes undergo citrullination, they become faster, stronger, and more durable. This discovery suggests that the very chemical change that triggers the immune system also gives the disease-causing enzymes a significant boost in their ability to damage tissue, creating a dangerous cycle of inflammation and destruction within the joints.
To understand how this works, the researchers started with a well-known enzyme called trypsin, which is often used in laboratories to break down proteins. They treated trypsin with the enzyme responsible for citrullination and then watched how it behaved. The results were clear: the treated enzyme cut through its targets much faster than the untreated version. It did not just work harder; it also lasted longer. Normally, these enzymes tend to wear themselves out by accidentally cutting their own parts, a process that limits how long they can function. However, the citrullinated versions resisted this self-destruction, remaining active for days while the untreated versions fell apart. The researchers also found that this chemical change made the enzyme's active site, the part that grabs onto the protein it needs to cut, more accessible, allowing it to work more efficiently without changing how tightly it held onto its target.
The team then moved from the test tube to the actual cells involved in rheumatoid arthritis. Neutrophils are a type of white blood cell that rushes to sites of infection or injury. Inside these cells are powerful enzymes, including proteinase-3, neutrophil elastase, and cathepsin G, which are designed to break down bacteria. In rheumatoid arthritis, these cells release their contents into the joint space. The researchers found that when these specific enzymes are citrullinated, they undergo the same transformation seen in trypsin: they become more active and more stable. This means that in the inflamed joint, the citrullinated enzymes are not only more numerous but also more potent, capable of causing significantly more damage to the surrounding tissue than their non-altered counterparts.
The study also revealed a direct link between this enhanced activity and the immune system's response. The researchers showed that the citrullinated enzymes are recognized by the immune system as targets. When they mixed blood serum from patients with rheumatoid arthritis with these modified enzymes, the antibodies in the blood latched onto them, forming large, stable complexes. This confirms that the body sees these supercharged enzymes as a threat. Furthermore, the researchers looked at samples from the lungs, a site where early signs of the disease often appear before joint symptoms begin. They found that in people at risk for developing rheumatoid arthritis, the activity of these enzymes in the lungs was higher, and this activity was closely tied to the presence of antibodies against the citrullinated versions. This suggests that the process of these enzymes becoming more active and triggering an immune response may start in the lungs long before the disease reaches the joints.
Inside the joint itself, the consequences of this activation are severe. The researchers tested how these citrullinated enzymes affected aggrecan, a major structural protein that gives cartilage its ability to absorb shock and support weight. They found that the citrullinated versions of the enzymes broke down aggrecan much more rapidly than the normal versions. This accelerated destruction helps explain how cartilage is lost in rheumatoid arthritis. Additionally, the study showed that these activated enzymes can directly stimulate the cells that line the joint, known as fibroblast-like synoviocytes. When these cells are exposed to the citrullinated enzymes, they release a flood of inflammatory signals that drive further pain and swelling. The researchers traced this reaction to a specific pathway in the cells, showing that the enhanced cutting power of the enzymes is what triggers the inflammation.
Perhaps most importantly, the study points toward a potential way to stop this cycle. The researchers tested a drug that blocks the enzyme responsible for citrullination. When they treated the citrullinated enzymes with this blocker, the enzymes lost their extra power and returned to a normal state. They also applied this blocker to fluid taken directly from the joints of patients with rheumatoid arthritis, and it successfully reduced the activity of the enzymes. This suggests that targeting the chemical change itself, rather than just the resulting inflammation, could be a viable strategy for treatment.
The findings offer a new perspective on how rheumatoid arthritis progresses. It appears that the chemical alteration of proteins does more than just confuse the immune system; it fundamentally changes the behavior of the enzymes involved, turning them into more aggressive and longer-lasting weapons of tissue destruction. By enhancing the speed and stability of these enzymes, citrullination creates a feedback loop where the disease becomes self-perpetuating. The research highlights that the chemical modification is not a passive marker of disease but an active driver of the damage seen in patients. While more work is needed to fully understand how this process begins and how it might be best treated in people, the study provides a clear mechanism for why these enzymes are so destructive and offers a promising new target for future therapies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.